Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Initiates Restructuring Program To Save Up To $475M Annually

Executive Summary

The medtech giant will simplify its organizational structure, consolidate operations and give more autonomy to its individual operating units.

You may also be interested in...



Medtronic Claims Share Gains In Cardiovascular And Neurostim

The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.

Medtronic Lays Out Plans To Achieve 5%+ Annual Growth

The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.

Medtronic ‘Plays Offense’ Despite Pandemic Challenges, Q1 Results Provide Optimism

Medtronic’s revenue of $6.5bn in the first quarter of fiscal 2021 represents a 17% fall year-over-year, but it still beat analysts’ projections.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel